Science 2.0 uses the resources of Web 2.0 to communicate between scientists, and with the general public. Web 3.0, in turn, has brought disruptive technologies such as semantic search, cloud computing and mobile applications into play. The term Pharma 3.0 anticipates the future relationship between drug makers and doctors with their patients in light of such technology. From Science 2.0 to Pharma 3.0 examines these developments, discussing the best and worst of Web 2.0 in science communication and health. Successes such as the Open Access phenomena and also less successful networks are covered. This title is divided into three parts. The first part considers the Web 2.0 revolution, and the promise of its impact on science communication and the state of Science 2.0. The second part looks at impact on Pharma and Health, including attempts to utilise digital in Pharma. The last part looks at the promising disruptive technologies of Web 3.0, including semantic search in biomedicine and enterprise platforms. The book concludes by looking forward to developments of ‘3.0’ in Pharma and STM publishing. Gives a global overview of success and failure in Science 2.0 Presents useful stories and lessons learned Gives a clear view of how semantic search is present in science platforms and its potential in STM publishing
Basset, H.: Enterprise 2.0 and Web 3.0. From Science 2.0 to Pharma 3.0, pp. 169–193 (2013). https://doi.org/10.1016/B978-1-84334-709-5.50006-5 26. McClure, R.: WritingResearchWriting: the semantic web and the future of the research ...
Advancing Open Science Sadia Vancauwenbergh. DOI: http://dx.doi.org/10.5772/intechopen.97815 [31] ... Science 3.0: Corrections to the science 2.0 paradigm (2013) [Internet]. 2013. ... Silber D, Boutin F. From science 2.0 to pharma 3.0.
From science 2.0 to pharma 3.0: semantic search and social media in the pharmaceutical industry and STM publishing. Elsevier. Bosch, J., & Eklund, U. (2012). Eternal embedded software: towards innovation experiment systems.
O 6 > 12 2.0 n.d. n.d. 8 . 9 9.5 7 > 12 3. O - - 17.8 20. 0 8 > 12 1.5 - - 13.2 12.4 9 > 12 1.5 - - 6. 1 7. 9 10 > 12 n.d. - - 5. O 4.5 11 5 1.0 n.d. - - 1.2 12 > 12 3.0 - - - 2.4 13 3 n.d. n.d. n.d. - O ... O 14 6 1.0 n.d. n.d. 5.6 5.
... shown in Table 1. according 2.0 4.6 9.2 9.4 3.6 4.9 0.8 2.4 2.5 1.1 2.0 2.1 1.7 2.0 7.6 3.9 4.1 1.8 3.7 2.6 Ga 0.5 0.3 0.4 0.5 0.4 1.3 0.4 0.5 0.2 0.4 3.1 0.5 0.4 0.4 0.6 0.7 0.7 Ti 2.3 4.8 1.4 1.9 7.1 1.2 5.2 1.9 16 2.0 1.8 3.0 3.0 ...
6.0 5.5 5.0 4.5 4.0 HOD 4.0 3.8 3.6 3.4 1.6 1.4 1.2 Ala CH Ala CH3 13C 13C 13C 13C 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm (a) Ala CH3 (b) 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm 0.5 s 1.0 s 1.5 s 2.0 s 3.0 s 4.0 s 5.0 s 6.0 s 10.0 s HOD ...
... [Mean] All 1.4 1.5 1.9 2.0 2.0 2.7 2.9 SMEs 1.4 1.5 2.0 1.9 2.1 2.8 2.9 MNCs 1.4 1.4 1.7 2.2 2.0 2.4 3.0 Chemical/pharma 1.0 1.6 1.3 1.8 1.8 1.9 2.9 Machinery 1.4 1.5 2.2 2.1 2.1 3.1 3.0 Electrical 1.5 1.5 2.0 2.0 2.1 2.7 2.8 SMEs ...
The Science and Technology of Dosage Forms Geoffrey D Tovey ... Disintegrant − 0 + Alginic acid 7.0 8.0 9.0 Croscarmellose 1.5 2.0 2.5 Crospovidone 2.0 3.0 4.0 Maize starch 7.5 10.0 12.5 Pregelatinised starch 7.5 10.0 12.5 Sodium ...
Distinctive Educational Programs: Strong emphasis on Problem Based Learning, transitional research, integrated curriculum and interdisciplinary programs. 4 year MD/MPH Program. 7 year combined MD/PhD program with Sackler School of ...
... io t a r t n e c n o 0.04 0.02 0.00 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 Distance from ... Distance from the compact surface (mm) (C) 0.12 (D) 0.12 0.10 0.10 0.08 0.08 0.06 0.06 C C 2.0 2.5 3.0 3.5 0.0 30 ...